Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3043% above fair value
$0.56+0.02 (+3.54%)
Close on Nov 17, 2026Market cap $77.98MP/E –Yield –
Rani Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Rani Therapeutics
Rani Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?